Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria.

Beeson JG, Drew DR, Boyle MJ, Feng G, Fowkes FJ, Richards JS.

FEMS Microbiol Rev. 2016 May;40(3):343-72. doi: 10.1093/femsre/fuw001. Epub 2016 Jan 31. Review.

2.

Progress and prospects for blood-stage malaria vaccines.

Miura K.

Expert Rev Vaccines. 2016 Jun;15(6):765-81. doi: 10.1586/14760584.2016.1141680. Epub 2016 Feb 3.

3.

Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.

Chitnis CE, Mukherjee P, Mehta S, Yazdani SS, Dhawan S, Shakri AR, Bhardwaj R, Gupta PK, Hans D, Mazumdar S, Singh B, Kumar S, Pandey G, Parulekar V, Imbault N, Shivyogi P, Godbole G, Mohan K, Leroy O, Singh K, Chauhan VS.

PLoS One. 2015 Apr 30;10(4):e0117820. doi: 10.1371/journal.pone.0117820. eCollection 2015. Erratum in: PLoS One. 2015;10(9):e0137816. Bharadwaj, Rukmini [corrected to Bhardwaj, Rukmini].

4.

Diversity and population structure of Plasmodium falciparum in Thailand based on the spatial and temporal haplotype patterns of the C-terminal 19-kDa domain of merozoite surface protein-1.

Simpalipan P, Pattaradilokrat S, Siripoon N, Seugorn A, Kaewthamasorn M, Butcher RD, Harnyuttanakorn P.

Malar J. 2014 Feb 12;13:54. doi: 10.1186/1475-2875-13-54.

5.

The evolutionary consequences of blood-stage vaccination on the rodent malaria Plasmodium chabaudi.

Barclay VC, Sim D, Chan BH, Nell LA, Rabaa MA, Bell AS, Anders RF, Read AF.

PLoS Biol. 2012;10(7):e1001368. doi: 10.1371/journal.pbio.1001368. Epub 2012 Jul 31.

6.

A review of malaria vaccine clinical projects based on the WHO rainbow table.

Schwartz L, Brown GV, Genton B, Moorthy VS.

Malar J. 2012 Jan 9;11:11. doi: 10.1186/1475-2875-11-11. Review.

7.

A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720.

McCarthy JS, Marjason J, Elliott S, Fahey P, Bang G, Malkin E, Tierney E, Aked-Hurditch H, Adda C, Cross N, Richards JS, Fowkes FJ, Boyle MJ, Long C, Druilhe P, Beeson JG, Anders RF.

PLoS One. 2011;6(9):e24413. doi: 10.1371/journal.pone.0024413. Epub 2011 Sep 19.

8.

Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol.

Bouillet LÉ, Dias MO, Dorigo NA, Moura AD, Russell B, Nosten F, Renia L, Braga EM, Gazzinelli RT, Rodrigues MM, Soares IS, Bruna-Romero O.

Infect Immun. 2011 Sep;79(9):3642-52. doi: 10.1128/IAI.05048-11. Epub 2011 Jul 5.

9.

Determination of the Plasmodium vivax schizont stage proteome.

Roobsoong W, Roytrakul S, Sattabongkot J, Li J, Udomsangpetch R, Cui L.

J Proteomics. 2011 Aug 24;74(9):1701-10. doi: 10.1016/j.jprot.2011.03.035. Epub 2011 Apr 13.

10.

Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine.

Zhu D, McClellan H, Dai W, Gebregeorgis E, Kidwell MA, Aebig J, Rausch KM, Martin LB, Ellis RD, Miller L, Wu Y.

Vaccine. 2011 May 9;29(20):3640-5. doi: 10.1016/j.vaccine.2011.03.015. Epub 2011 Apr 8.

11.

Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.

Herrera S, Fernández OL, Vera O, Cárdenas W, Ramírez O, Palacios R, Chen-Mok M, Corradin G, Arévalo-Herrera M.

Am J Trop Med Hyg. 2011 Feb;84(2 Suppl):12-20. doi: 10.4269/ajtmh.2011.09-0516.

12.

Blood stage vaccines for Plasmodium falciparum: current status and the way forward.

Ellis RD, Sagara I, Doumbo O, Wu Y.

Hum Vaccin. 2010 Aug;6(8):627-34. Review.

13.

Epitope mapping of PfCP-2.9, an asexual blood-stage vaccine candidate of Plasmodium falciparum.

Li C, Wang R, Wu Y, Zhang D, He Z, Pan W.

Malar J. 2010 Apr 12;9:94. doi: 10.1186/1475-2875-9-94.

14.

Solution structure of a Plasmodium falciparum AMA-1/MSP 1 chimeric protein vaccine candidate (PfCP-2.9) for malaria.

Peng H, Hu Y, Zhou A, Jin C, Pan W.

Malar J. 2010 Mar 18;9:76. doi: 10.1186/1475-2875-9-76.

15.

Protein-DNA complex is the exclusive malaria parasite component that activates dendritic cells and triggers innate immune responses.

Wu X, Gowda NM, Kumar S, Gowda DC.

J Immunol. 2010 Apr 15;184(8):4338-48. doi: 10.4049/jimmunol.0903824. Epub 2010 Mar 15.

16.

Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults.

Ellis RD, Martin LB, Shaffer D, Long CA, Miura K, Fay MP, Narum DL, Zhu D, Mullen GE, Mahanty S, Miller LH, Durbin AP.

PLoS One. 2010 Jan 22;5(1):e8787. doi: 10.1371/journal.pone.0008787.

17.

The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis.

Fowkes FJ, Richards JS, Simpson JA, Beeson JG.

PLoS Med. 2010 Jan 19;7(1):e1000218. doi: 10.1371/journal.pmed.1000218. Review.

18.

Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.

Pierce MA, Ellis RD, Martin LB, Malkin E, Tierney E, Miura K, Fay MP, Marjason J, Elliott SL, Mullen GE, Rausch K, Zhu D, Long CA, Miller LH.

Vaccine. 2010 Mar 2;28(10):2236-42. doi: 10.1016/j.vaccine.2009.12.049. Epub 2010 Jan 4.

19.

Advances and challenges in malaria vaccine development.

Wang R, Smith JD, Kappe SH.

Expert Rev Mol Med. 2009 Dec 16;11:e39. doi: 10.1017/S1462399409001318.

20.

Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of antigenicity studies in humans.

Demanga CG, Daher LJ, Prieur E, Blanc C, Pérignon JL, Bouharoun-Tayoun H, Druilhe P.

Infect Immun. 2010 Jan;78(1):486-94. doi: 10.1128/IAI.01359-08. Epub 2009 Nov 2.

Items per page

Supplemental Content

Write to the Help Desk